Heart failure (HF) is a significant global health challenge, with rising prevalence and a complex, multifactorial pathophysiology. Emerging evidence suggests that disruptions in redox signaling pathways and genetic mutations play critical, synergistic roles in the development and progression of HF. This comprehensive review synthesizes current knowledge on how redox imbalance and genetic alterations interact to drive cardiac dysfunction and critically evaluates the therapeutic strategies targeting these mechanisms. We begin by introducing the basic concepts of redox biology and its role in maintaining cardiac homeostasis. Next, we examine the specific redox signaling pathways and genetic mutations implicated in HF pathogenesis, highlighting the latest mechanistic insights and findings from human studies. The complex interplay between redox dysregulation and genetic factors is explored, including their synergistic effects, compensatory mechanisms, and illustrative case studies. We also review current therapeutic strategies aimed at restoring redox balance and correcting underlying genetic mutations, discussing their progress and limitations. Finally, we present the latest research advances, identify critical knowledge gaps, and propose future directions for both basic and translational research. Understanding the redox–genetic axis is key to developing novel, targeted therapies to address the growing HF epidemic.
While pressure-wire based fractional flow reserve (FFR) is considered the gold standard for evaluating coronary lesion significance, its use in daily clinical practice remains limited.Angiography derived vessel based FFR (vFFR) offers a promising alternative, without the need for pressure wires or hyperaemia by leveraging three dimensional quantitative coronary angiography. This study evaluated the concordance between angiography derived vFFR and invasive FFR in patients with intermediate coronary stenosis. Retrospectively, coronary angiograms of patients who underwent adenosine based FFR from January 2022 until January 2025 for borderline lesions were retrieved from the health management information system (HMIS) software and processed by a blinded core laboratory for vFFR computation. Correlation and diagnostic performance were assessed using Mann-Whitney U testing, Spearman correlation, Bland-Altman analysis, chi-square analysis, ROC curves, and binary logistic regression. The median age of the cohort was 61 years, and 30.6% were female. LAD was the most commonly assessed artery. The median FFR and vFFR values were 0.85 and 0.83, respectively. Overall, 33.9% of lesions were classified as ischemic by FFR. A strong correlation was found between vFFR and invasive FFR (r = 0.808, p < 0.001). The diagnostic performance of vFFR was excellent with an AUC of 0.92. At a vFFR cut off of 0.80, sensitivity was 85.7% and specificity 80.5% with a diagnostic accuracy of 82.3%. Subgroup analysis demonstrated reduced correlations in bifurcation (r = 0.661) and calcified lesions (r = 0.733). In this retrospective cohort, angiography derived vFFR demonstrated good correlation and diagnostic performance compared with invasive FFR for the assessment of intermediate coronary lesions.